The influence of postoperative morbidity on long-term quality of life outcomes following pelvic exenteration
European Journal of Surgical Oncology · 2024
DOI: 10.1016/j.ejso.2024.108640 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2024. Verfasst von Preet G S Makker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Faculty of Medicine and Health, Central…. Hauptthemen laut MEDLINE: Pelvic Exenteration, Quality of Life, Postoperative Complications, Length of Stay. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Pelvic exenteration provides significant survival benefits for selected patients diagnosed with locally advanced rectal cancer. However, in-hospital postoperative morbidity such as abdominal abscess, sepsis, and anastomotic leak remain highly prevalent, which can have short/long-term impacts on patient quality of life (QoL). The aim of this study was to determine the influence of postoperative morbidity on QoL outcomes in patients following pelvic exenteration. METHODS: This prospective cohort study included patients who underwent pelvic exenteration at a tertiary teaching hospital in Sydney, between 2008 and 2023. QoL measures were collected at baseline, 6, 12, 18, 24, 36, 48, and 60 months using the short-form 36 (SF-36v2) survey. The predictors included variables relating to postoperative morbidity, including hospital and ICU length of stay (LOS), post-discharge mortality and the number of postoperative complications. Mixed-effects analyses were used to determine the influence of these postoperative outcomes on physical and mental QoL trajectories. RESULTS: This study included 674 patients, with a median age of 61 years. Shorter hospital and ICU LOS, and fewer or no postoperative complications were associated with higher physical QoL scores across all time points. Conversely, postoperative morbidity did not exhibit a significant impact on mental QoL scores. Furthermore, there was a longitudinal improvement in mental QoL outcomes compared to baseline, independent of postoperative morbidity. CONCLUSION: Postoperative morbidity significantly impacted physical QoL outcomes after pelvic exenteration, whereas mental QoL outcomes were not influenced. Interventions aimed at mitigating postoperative morbidity may hold the potential to enhance long-term QoL outcomes following pelvic exenteration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Faculty of Medicine and Health, Central Clinical School, The University of Sydney, New South Wales, Australia…
- Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
- The Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, Australia; Cancer Care Research Unit, Sydney Local Health District, Sydney, 2050, Australia.
Zitieren
APA
Makker, P. G. S., Koh, C. E., Solomon, M., El-Hayek, J., Kim, B., & Steffens, D. (2024). The influence of postoperative morbidity on long-term quality of life outcomes following pelvic exenteration. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2024.108640
Vancouver
Makker PGS, Koh CE, Solomon M, El-Hayek J, Kim B, Steffens D. The influence of postoperative morbidity on long-term quality of life outcomes following pelvic exenteration. European Journal of Surgical Oncology. 2024. doi:10.1016/j.ejso.2024.108640
BibTeX
@article{Makker2024,
author = {Makker, Preet G S and Koh, Cherry E and Solomon, Michael and El-Hayek, Jessica and Kim, Bora and Steffens, Daniel},
title = {The influence of postoperative morbidity on long-term quality of life outcomes following pelvic exenteration},
journal = {European Journal of Surgical Oncology},
year = {2024},
doi = {10.1016/j.ejso.2024.108640}
}
EUVIMED